Cargando…
Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by gen...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572793/ https://www.ncbi.nlm.nih.gov/pubmed/37834042 http://dx.doi.org/10.3390/ijms241914594 |
_version_ | 1785120315402092544 |
---|---|
author | Gomez-Gaitan, Esteban Alejandro Garcia-Ortega, Yessica Eleanet Saldaña-Cruz, Ana Miriam Contreras-Haro, Betsabe Gamez-Nava, Jorge Ivan Perez-Guerrero, Emilio Edsaul Nava-Valdivia, Cesar Arturo Gallardo-Moya, Sergio Martinez-Hernandez, Alejandra Gonzalez Lopez, Laura Rios-Gonzalez, Blanca Esthela Marquez-Pedroza, Jazmin Mendez-del Villar, Miriam Esparza-Guerrero, Yussef Villagomez-Vega, Alejandra Macias Islas, Miguel Angel |
author_facet | Gomez-Gaitan, Esteban Alejandro Garcia-Ortega, Yessica Eleanet Saldaña-Cruz, Ana Miriam Contreras-Haro, Betsabe Gamez-Nava, Jorge Ivan Perez-Guerrero, Emilio Edsaul Nava-Valdivia, Cesar Arturo Gallardo-Moya, Sergio Martinez-Hernandez, Alejandra Gonzalez Lopez, Laura Rios-Gonzalez, Blanca Esthela Marquez-Pedroza, Jazmin Mendez-del Villar, Miriam Esparza-Guerrero, Yussef Villagomez-Vega, Alejandra Macias Islas, Miguel Angel |
author_sort | Gomez-Gaitan, Esteban Alejandro |
collection | PubMed |
description | Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis. No evidence of disease activity based on the absence of clinical relapse, disability progression or radiological activity (NEDA-3) was used to classify the therapeutic response. Patients were classified as follows: (a) controls: patients who achieved NEDA-3; (b) cases: patients who did not achieve NEDA-3. DNA was extracted from peripheral blood leukocytes. HLA-DRB1*0403 genetic variant was analyzed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. NEDA-3 was achieved in 86.7% of MS patients treated with DMTs. Genotype frequencies were GG 50.5%, GA 34.3%, and AA 15.2%. No differences were observed in the genetic variant AA between patients who achieved NEDA-3 versus patients who did not achieve NEDA-3 (48.7% vs. 43.1%, p = 0.6). We concluded that in Mexican patients with MS, HLA-DRB1*0403 was not associated with the therapeutic response to DMTs. |
format | Online Article Text |
id | pubmed-10572793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105727932023-10-14 Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study Gomez-Gaitan, Esteban Alejandro Garcia-Ortega, Yessica Eleanet Saldaña-Cruz, Ana Miriam Contreras-Haro, Betsabe Gamez-Nava, Jorge Ivan Perez-Guerrero, Emilio Edsaul Nava-Valdivia, Cesar Arturo Gallardo-Moya, Sergio Martinez-Hernandez, Alejandra Gonzalez Lopez, Laura Rios-Gonzalez, Blanca Esthela Marquez-Pedroza, Jazmin Mendez-del Villar, Miriam Esparza-Guerrero, Yussef Villagomez-Vega, Alejandra Macias Islas, Miguel Angel Int J Mol Sci Article Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis. No evidence of disease activity based on the absence of clinical relapse, disability progression or radiological activity (NEDA-3) was used to classify the therapeutic response. Patients were classified as follows: (a) controls: patients who achieved NEDA-3; (b) cases: patients who did not achieve NEDA-3. DNA was extracted from peripheral blood leukocytes. HLA-DRB1*0403 genetic variant was analyzed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. NEDA-3 was achieved in 86.7% of MS patients treated with DMTs. Genotype frequencies were GG 50.5%, GA 34.3%, and AA 15.2%. No differences were observed in the genetic variant AA between patients who achieved NEDA-3 versus patients who did not achieve NEDA-3 (48.7% vs. 43.1%, p = 0.6). We concluded that in Mexican patients with MS, HLA-DRB1*0403 was not associated with the therapeutic response to DMTs. MDPI 2023-09-27 /pmc/articles/PMC10572793/ /pubmed/37834042 http://dx.doi.org/10.3390/ijms241914594 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gomez-Gaitan, Esteban Alejandro Garcia-Ortega, Yessica Eleanet Saldaña-Cruz, Ana Miriam Contreras-Haro, Betsabe Gamez-Nava, Jorge Ivan Perez-Guerrero, Emilio Edsaul Nava-Valdivia, Cesar Arturo Gallardo-Moya, Sergio Martinez-Hernandez, Alejandra Gonzalez Lopez, Laura Rios-Gonzalez, Blanca Esthela Marquez-Pedroza, Jazmin Mendez-del Villar, Miriam Esparza-Guerrero, Yussef Villagomez-Vega, Alejandra Macias Islas, Miguel Angel Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study |
title | Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study |
title_full | Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study |
title_fullStr | Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study |
title_full_unstemmed | Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study |
title_short | Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study |
title_sort | genetic variant hla-drb1*0403 and therapeutic response to disease-modifying therapies in multiple sclerosis: a case-control study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572793/ https://www.ncbi.nlm.nih.gov/pubmed/37834042 http://dx.doi.org/10.3390/ijms241914594 |
work_keys_str_mv | AT gomezgaitanestebanalejandro geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT garciaortegayessicaeleanet geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT saldanacruzanamiriam geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT contrerasharobetsabe geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT gameznavajorgeivan geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT perezguerreroemilioedsaul geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT navavaldiviacesararturo geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT gallardomoyasergio geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT martinezhernandezalejandra geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT gonzalezlopezlaura geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT riosgonzalezblancaesthela geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT marquezpedrozajazmin geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT mendezdelvillarmiriam geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT esparzaguerreroyussef geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT villagomezvegaalejandra geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy AT maciasislasmiguelangel geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy |